Nils Lonberg, Ph.D.
Senior Vice President, Oncology Discovery Biology
Bristol-Myers Squibb Company
Dr. Lonberg began his career in the life sciences industry at GenPharm International that developed genetically engineered strains of mice with germline-configuration human immunoglobulin genes, which have been used to discover over two dozen clinical-stage human sequence antibodies. GenPharm was acquired by Medarex, which subsequently was acquired by Bristol-Myers Squibb in 2009. He is an inventor on 36 issued U.S. patents, including patents covering seven marketed therapeutic drugs.